Menactra MCV4 Supply Update

1
Menactra (MCV4)Supply Update

• Gregory S. Wallace, M.D., M.S., M.P.H.
• Chief, Vaccine Supply Assurance Branch
• Immunization Services Division
• National Center for Immunization Respiratory
  Diseases
• Centers for Disease Control and Prevention

2
Meningococcal Conjugate Vaccine Introduction

• January 2005 Licensed by FDA
• February 2005 ACIP Recommendation VFC
  Resolution
• April 2005 CDC Contract
• May 2005 Recommendations Published in MMWR

3
Meningococcal Conjugate Vaccine Recommendations

• Routine Vaccination at the 11-12 year old visit
• Previously unvaccinated at High School Entry
• Populations at Increased Risk for Disease
  (including college freshmen living in
  dormitories)

4
Initial Vaccine Supply Demand

• High Demand for Vaccine starting in June 2005
• Order Limits and Back Orders
• Demand initially highest in college freshman
• CDC Emphasizes Recommendations

5
Claims Data Through 8/20/05
6
Claims Data Through 3/26/06
7
1st Year MCV4 Distribution
8
Cumulative MCV4 Supply
9
Summary of 1st Year and 2nd Year Projections

• High Summer Demand
• Complaints/Concerns Diminished in Fall/Winter
• 4.2 millions doses distributed Year 1
• Project 6 million doses for Year 2
• Higher Summer Demand Expected Year 2
• Approximately Equal of Summer Doses

10
(No Transcript)
11
Interim Recommendations

• Defer 11-12 year old dose
• Prioritize High-School Entry and College
  Freshman living in dorms
• Continue High-Risk groups

12
Lessons (Re) Learned

• Open Communication with Stakeholders Markedly
  Improves Interventions
• Implementing New Vaccines New Recommendations
  Increasingly Complicated
• Supply Demand is often unpredictable
  necessitating a dynamic transparency